Lincoln, Nebraska, April 18, 2023 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ/:NRC) today announced that it will provide an online web simulcast of its 2023 first quarter earnings conference call on Wednesday, May 3, 2023. The Company’s results for the 2023 first quarter will be released after the close of the market on Tuesday, May 2, 2023.
The live broadcast of National Research Corporation’s conference call will begin at 11:00 a.m. Eastern Time on May 3, 2023. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
A live audio webcast can be accessed at https://events.q4inc.com/attendee/253347934. The webcast will also be available for replay.
For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health’s patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it., or visit www.nrchealth.com.

| Last Trade: | US$16.99 |
| Daily Change: | -0.28 -1.62 |
| Daily Volume: | 42,764 |
| Market Cap: | US$384.990M |
November 13, 2025 November 06, 2025 October 27, 2025 July 28, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load